ArticleVaccine2007
Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 58 citations in OpenAlex.
- Trial
- Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B.Clinical and vaccine immunology : CVI · 2014Trial
- Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.Clinical immunology (Orlando, Fla.) · 2011Trial
- Trial
- Multivalent vaccines for invasiveInfection and immunity · 2026Review
- Controlled human infectious models, a path forward in uncovering immunological correlates of protection: Lessons from enteric fevers studies.Frontiers in microbiology · 2022Review
- The role of vaccines in combatting antimicrobial resistance.Nature reviews. Microbiology · 2021Review
- B Cells Control Mucosal-Associated Invariant T Cell Responses toFrontiers in immunology · 2021Article
- Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.Clinical & translational immunology · 2021Article
- Differential functional patterns of memory CD4Vaccine · 2020Article
- Cell mediated immune responses elicited in volunteers following immunization with candidate live oral Salmonella enterica serovar Paratyphi A attenuated vaccine strain CVD 1902.Clinical immunology (Orlando, Fla.) · 2019Article
- Effect of the live oral attenuated typhoid vaccine, Ty21a, on systemic and terminal ileum mucosal CD4+ T memory responses in humans.International immunology · 2019Article
- Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? CD8 T-Cell-Mediated Protective Immunity and Vaccination against Enteric Bacteria.Cold Spring Harbor perspectives in biology · 2018Review
- Bi-valent polysaccharides of Vi capsular and O9 O-antigen in attenuatedNPJ vaccines · 2018Article
- Salmonella infection: Interplay between the bacteria and host immune system.Immunology letters · 2017Review
- Use of a novel antigen expressing system to study the Salmonella enterica serovar Typhi protein recognition by T cells.PLoS neglected tropical diseases · 2017Article
- Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.Clinical and vaccine immunology : CVI · 2017Article
- Importance ofFrontiers in immunology · 2017Article
- Cross-reactive multifunctional CD4+ T cell responses against Salmonella enterica serovars Typhi, Paratyphi A and Paratyphi B in humans following immunization with live oral typhoid vaccine Ty21a.Clinical immunology (Orlando, Fla.) · 2016Article
- Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method.Microbial pathogenesis · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
CVD 909 is a novel live attenuated S. Typhi oral vaccine candidate derived from strain CVD 908-htrA which constitutively expresses Vi. Herein we investigated whether the genetic manipulations involved in modifying CVD 908-htrA altered its ability to induce potent T-cell immune responses (CMI) after a single dose (five subjects) and, in a separate trial, whether a second dose (eight subjects) further enhanced its immunogenicity. In these clinical trials we observed that CVD 909 immunization elicits a wide array of CMI, including cytotoxic T cells (CTL), IFN-gamma, TNF-alpha and IL-10 (but not IL-2, IL-4 or IL-5) production, and proliferation to S. Typhi antigens. However, the administration of a second dose did not result in increases in CMI. These results suggest that the genetic manipulations to constitutively express Vi did not adversely affect the ability of CVD 909 to elicit a wide array of CMI responses. These observations add impetus for the continuing evaluation of CVD 909 as a typhoid vaccine candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.